FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
This article was originally published in The Tan Sheet
Executive Summary
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms
You may also be interested in...
FDA Generic Final Rule Requires Polymorph Test Data For Patent Listing
FDA's final rule to reform Hatch/Waxman requires an innovator company to test data to establish that a polymorph claimed in a patent is the same as the active ingredient in the NDA
Generic Drug Reforms: FTC Notification Bill Appears Ready To Move In 2003
A bill to require reporting of brand/generic patent settlements to the Federal Trade Commission appears ready to move early in the 108th Congress
FTC Backs Single 30-Month Stay On Generic Approvals In Patent Litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation